Exploratory study to determine predictive factors of effectiveness of nab-paclitaxel in breast cancer (Expect study)

Phase 2

Recruiting

• Conditions: Breast cancer

• Registration Number: JPRN-UMIN000009526
• Lead Sponsor: Toho University School of Medicine, Medical Center, Ohashi Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-12-11
• Study Completion: 2018-12-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: Female
• Target Recruitment: 40

Inclusion Criteria

Not provided

Exclusion Criteria

1.History of hypersensitivity reaction 2.HER2 positive confirmed by IHC or FISH 3. Active another cancer 4.Other severe complications, such as infection, diarrhea, intestinal tract paralysis, ileus, uncontrollable diabetes,uncontrollable angina, myocardial infarction within 6 months, heart failure, Pulmonary fibrosis or interstitial pneumonia, cerebrovascular disorder 5.With symptomatic brain cancer 6.With mental disorder which become problem on clinical practice 7.With serious bone marrow suppression, a renal damage, a liver damage 8.With serious pleural effusion or ascites 9.With infection or febrile infection 10. Hypersensitivity reaction of nab-paclitaxel or paclitaxel 11.During administration of flucytosine, phenytoin, warfarin potassium 8. Physician judged improper to entry this trial

Study & Design

• Study Type: Interventional
• Study Design: Not specified